PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Non-clinical Evaluations for Anti-cancer Drugs with ICH S9 Guideline Q&A – What the Industry Needs to Know

The ICH S9 Guideline Q&A document – published in June 2018 – is designed to clarify some of the most common challenges experienced across the industry when implementing ICH S9. Here, Robert Turcan at Envigo highlights a few key areas selected based on the advice sought by their customers during the development of their anti-cancer pharmaceuticals. He concludes with a consideration of the outlook for oncology programmes, as well as recent FDA approvals.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2019/04/Non-clinical-evaluations-for-anti-cancer.pdf” width=”100%” height=”900px” style=”border:0;”]

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40